Ginkgo Biloba Prevention Trial in Older Individuals

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine the effect of 240mg/day Ginkgo biloba in decreasing the incidence of dementia and specifically Alzheimer's disease (AD), slowing cognitive decline and functional disability, reducing incidence of cardiovascular disease, and decreasing total mortality.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Center for Complementary and Integrative Health (NCCIH)
• Collaborators: National Heart, Lung, and Blood Institute (NHLBI); National Institute of Neurological Disorders and Stroke (NINDS); National Institute on Aging (NIA); Office of Dietary Supplements (ODS)

Criteria

Inclusion Criteria:

• Non-demented participants

• Willing to participate in a seven-year follow-up trial of Ginkgo Biloba

• English is their usual language

• Willing informant who has frequent contact with the participant

Exclusion Criteria:

• Currently on anticoagulant therapy

• Cancer diagnosed and treated within the past two years (except for skin cancer)

• Participant with class III - IV congestive heart failure

• Currently being treated with psychopharmacological drugs for depression

• Hospitalized for depression within the last year

• Taking Aricept (or similar agents) for cognitive problems or dementia

• Baseline blood creatinine >2

• Baseline SGGT is a marker of liver function (3 x normal>or=90 IU)

• Baseline hematocrit<30

• Baseline white blood count>or=15,000